1. Polyglucosan body myopathy 1 may cause cognitive impairment: a case report from China.
- Author
-
Chen, Lin, Wang, Nan, Hu, Wenbin, Yu, Xuen, Yang, Renming, Han, Yongzhu, Yan, Yan, Nian, Na, and Sha, Congbo
- Subjects
NEMALINE myopathy ,COGNITION disorders ,GLYCOGEN storage disease ,MUSCLE diseases ,MILD cognitive impairment ,SKELETAL muscle - Abstract
Background: Polyglucosan body myopathy 1 (PGBM1) is a type of glycogen storage disease that can cause skeletal muscle myopathy and cardiomyopathy with or without immunodeficiency due to a pathogenic mutation in the RBCK1 gene. PGBM1 has been reported in only 14 European and American families, and no cognitive impairment phenotype was reported. Its prevalence in Asia is unknown.Case Presentation: We report a Chinese boy with teenage onset of skeletal muscle myopathy and mild cognitive impairment. Whole-exome sequencing analysis identified a homozygous missense mutation in RBCK1 (c.1411G > A:p.Glu471Lys). A muscle biopsy indicated the accumulation of periodic acid-Schiff-positive material, which could be ubiquitinated by immunohistochemistry with an anti-ubiquitin antibody. In skeletal muscle tissue, HOIL-1 and HOIP protein levels were lower than those in the control, confirming the phenotype of an RBCK1 mutation. MRI revealed abnormal cerebral white matter signals. Immune system and cardiac examination found no abnormalities. The patient was diagnosed with PGBM1 with no effective treatment.Conclusions: This case from China with a novel homozygous missense mutation in RBCK1 extends the phenotypic spectrum and geographical distribution of PGBM 1, which may cause cerebral white matter changes and cognitive impairment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF